Studies on effects of Andrographis paniculata (Burm.f.) and Andrographis lineata nees (Family: Acanthaceae) extracts against two mosquitoes Culex quinquefasciatus (Say.) and Aedes aegypti (Linn.).

OBJECTIVE: To investigate the studies on effects of Andrographis paniculata (A. paniculata) (Burm.f.) and Andrographis lineata (A. lineata) nees (Family: Acanthaceae) extracts against two mosquitoes Culex quinquefasciatus (Cx. quinquefasciatus) (Say.) and Aedes aegypti (Ae. aegypti) (Linn.). METHODS: The aqueous and petroleum ether extracts of two plant species, A. paniculata and A. lineate were examined against the larvae of A. aegypti (L.) and Cx. quinquefasciatus with gradually increasing concentration ie. from 50 to 200 ppm of solvent extracts and to test their activity in combination with each other. RESULTS: In a 24 h bioassay experiment with plant extracts, highest mortalities were recorded at 200 ppm of concentrations for leaves of A. lineta and A. paniculata individually. For combination effect, only 150 ppm of the mixture of solvent extracts of petroleum ether: aqueous (1:1) extracts showed 100% mortality after 24 h of exposure. CONCLUSIONS: The results show that, insecticides of plant combination is ecofriend and has better larvicidal activity compared to individual extracts.

Oncolytic poxvirus armed with Fas ligand leads to induction of cellular Fas receptor and selective viral replication in FasR-negative cancer.

Tumor necrosis factor superfamily members, including Fas ligand and TRAIL, have been studied extensively for cancer therapy, including as components of gene therapy. We examined the use of FasL expression to achieve tumor-selective replication of an oncolytic poxvirus (vFasL), and explored its biology and therapeutic efficacy for FasR- and FasR+ cancers. Infection of FasR+ normal and MC38 cancer cells by vFasL led to abortive viral replication owing to acute apoptosis and subsequently showed both reduced pathogenicity in non-tumor-bearing mice and reduced efficacy in FasR+ tumor-bearing mice. Infection of FasR- B16 cancer cells by vFasL led to efficient viral replication, followed by late induction of FasR and subsequent apoptosis. Treatment with vFasL as compared with its parental virus (vJS6) led to increased tumor regression and prolonged survival of mice with FasR- cancer (B16) but not with FasR+ cancer (MC38). The delayed induction of FasR by viral infection in FasR- cells provides for potential increased efficacy beyond the limit of the direct oncolytic effect. FasR induction provides one mechanism for tumor-selective replication of oncolytic poxviruses in FasR- cancers with enhanced safety. The overall result is both a safer and more effective oncolytic virus for FasR- cancer.